← Leaderboards
Yogesh Chander
Lucigen Corporation
$1,893,916
Attributed
$2,020,033
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $874.6K · FY2013–22$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,515,725 · 2
CDC$504,308 · 2
By mechanism
R33$1,302,583 · 1
R43$504,308 · 2
R21$213,142 · 1
Top collaborators
- Jeniel E Nett1 shared
Most similar at Lucigen Corporation
Same institution · by research overlap
- David Alan Mead$5,620,270
- Dipankar Manna$783,086
- Thomas William Schoenfeld$2,716,093
- Michael James Moser$1,297,546
- Chengcang Charles Wu$7,371,324
Others in their field
Top investigators on “Pathogen”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$343,790,695
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
- Jeffrey P Krischer · University Of South Florida$130,496,919
- Mark S Klempner · Tufts Medical Center$128,021,180
- Timothy Stedman · American Type Culture Collection$122,230,581
- Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai$99,962,183
Research focus
PathogenDesignInnovationPoint Of CareMediatingDetectionSamplingTrainingMolecularPerformanceNucleic AcidsPreparationReactionEquipmentBasePolymeraseReagentResistanceAmplification DetectionPreventRna-Directed Dna PolymeraseEnzymesCostDiagnostic
Grant awards (6)
PA-21-259, SBIR, Phase I, Rapid molecular diagnostic assay for detection of Candida auris at point of care$252,235
R43 · FY2022 · CK · contact PI
Rapid molecular diagnostic assay for detection of Hepatitis C virus at point of care$252,073
R43 · FY2022 · PS · contact PI
Rapid Field Appropriate Diagnostics for Select Biodefense and Emerging Pathogens$450,870
R33 · FY2015 · AI · contact PI
Rapid Field Appropriate Diagnostics of Select Emerging and Biodefense Pathogens$423,743
R33 · FY2015 · AI · contact PI
Rapid Field Appropriate Diagnostics for Select Biodefense and Emerging Pathogens$427,970
R33 · FY2014 · AI · contact PI
Rapid Field Appropriate Diagnostics for Select Biodefense and Emerging Pathogens$213,142
R21 · FY2013 · AI · contact PI